data + articles · 4 listed
newest 2026spec sheet11 rows
JXL082 is an experimental small-molecule inhibitor of the mitochondrial pyruvate carrier (MPC) investigated as a topical candidate for hair loss. It belongs to a family of MPC-blocking compounds related to the prototype UK-5099 and the clinical candidate PP405, which are studied for their ability to reawaken dormant hair-follicle stem cells [1][4]. JXL082 has not been the subject of any published peer-reviewed human trial and exists as a preclinical research chemical; it has also been offered informally through online sellers outside approved medical channels.
- Targets a genuinely novel metabolic hair-growth mechanism
- Built for topical use to limit body-wide exposure
- Backed by solid preclinical MPC-to-lactate follicle biology
- Part of the same mechanism as the clinical candidate PP405
- Does not rely on hormones like finasteride
- Accelerated hair regrowth shown for related MPC inhibitors in mice
Overview
JXL082 is an experimental compound classed as a mitochondrial pyruvate carrier inhibitor, a small molecule that interferes with a specific step of cellular energy metabolism [1][3]. It was developed as a candidate topical treatment for androgenetic alopecia, the common pattern form of hair loss, and it belongs to the same chemical and pharmacological lineage as the widely used research tool UK-5099 and the more advanced clinical candidate PP405 [1][4]. Compounds of this type are generally studied in topical form so that their action is concentrated at the scalp [3].
Interest in this class grew from laboratory research on the metabolism of hair-follicle stem cells. A 2017 study at the University of California, Los Angeles reported that these stem cells depend on glycolysis and lactate production to switch out of dormancy, and that inhibiting the mitochondrial pyruvate carrier raised lactate and accelerated the hair cycle in mice [1]. That finding prompted a search for drug-like carrier inhibitors, and JXL082 is one of several such molecules explored as a hair-growth agent [1][4].
The evidence specific to JXL082 is limited. The underlying carrier-to-lactate mechanism is supported by animal and cell studies, and related inhibitors have promoted regrowth in shaved or depilated mice, but there is no published peer-reviewed human trial of JXL082 itself [3][4]. Work in cultured human hair follicles has added an important caution, showing that carrier inhibition can provoke a metabolic stress response that suppresses rather than stimulates follicle-cell proliferation, so the mouse results may not carry over cleanly to people [2].
JXL082 is not an approved medicine and holds no marketing authorization in any country. It has circulated in a grey-market fashion through online sellers offering it for hair loss, so the identity, purity, and safety of material obtained this way are not independently verified. It is best regarded as a preclinical research compound rather than a treatment.
Because formal human safety and efficacy data are absent, the risks of using JXL082 are not well defined [2]. Its place in current discussion rests on the plausibility of the mitochondrial pyruvate carrier mechanism rather than on established clinical results [1].
Mechanism
JXL082 is designed to inhibit the pyruvate carrier, the protein complex that transports pyruvate produced by glycolysis into the mitochondria to fuel oxidative metabolism [1][3]. Blocking this carrier forces cells to divert pyruvate toward the production of lactate instead [1]. Research on hair-follicle biology has shown that hair-follicle stem cells rely on this glycolytic, lactate-generating state to move from their normally dormant condition into an active, dividing one; deleting the carrier or the lactate-producing enzyme changes how readily these cells are switched on [1].
On this basis, small molecules that inhibit the carrier and raise lactate, of which UK-5099 is the prototype, have been shown to push resting follicles into the growth phase of the hair cycle and to promote regrowth when applied topically to mice [1][3][4]. JXL082 is one such carrier inhibitor advanced as a hair-loss candidate within this line of work [4]. The picture is not entirely straightforward, however; in cultured human hair follicles, blocking the carrier with UK-5099 triggered a metabolic stress response that halted rather than promoted cell division, indicating that findings in mouse models may not translate directly to human tissue [2].
receptor fingerprint
pyruvate carrier (MPC)Inhibition, shifting pyruvate toward lactate
Hair follicle stem cell activation (via LDHA/lactate)Promotes activation from the resting state
Hair cycle (telogen to anagen transition)Accelerates cycle onset
Safetyrisks and cautions, not medical advice
JXL082 is an experimental topical mitochondrial pyruvate carrier (MPC) inhibitor aimed at hair regrowth, and it is not an approved medicine; evidence is confined to preclinical and early research work. As a result there is no documented human side-effect profile, no tolerability data, and no established contraindications; the compound is sold grey-market and labeled for research use rather than human application. The honest risk here is largely unknown-unknowns plus sourcing: purity, concentration and formulation of grey-market material are unverified, and MPC inhibition is a systemic metabolic mechanism whose off-target consequences from repeated skin exposure have not been studied. Local reactions typical of any topical (irritation, contact dermatitis) are plausible but not formally characterized. Users should treat it as an unvalidated experimental agent.
Subjective profileweighing the evidence above
Not ready for a scalp. It is a preclinical research chemical with no published human trial of its own, sold grey-market, and in cultured human follicles blocking the carrier suppressed growth rather than driving it. PP405 is the version of this idea actually being tested in people.
Resources
This entry is here for reference.
Research
- 2017first citedLactate dehydrogenase activity drives hair follicle stem cell activation
- 2026most recentDiscovery and evaluation of SIPI11594: a novel mitochondrial pyruvate carrier inhibitor with an…
- 1.Lactate dehydrogenase activity drives hair follicle stem cell activation
- 2.Activation of the integrated stress response in human hair follicles
- 3.Design, synthesis and biological evaluation of novel cyano-cinnamate derivatives as mitochondrial pyruvate carrier inhibitors
- 4.Discovery and evaluation of SIPI11594: a novel mitochondrial pyruvate carrier inhibitor with anti-hair loss efficacy
4 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is JXL082 a JAK inhibitor?
No. That label gets attached to it online but is wrong. It is a mitochondrial pyruvate carrier (MPC) inhibitor working through follicle lactate metabolism.
Is there human data?
Not for JXL082 itself. The evidence is preclinical, mainly rodent studies of the MPC-to-lactate hair-cycle mechanism.
How is it related to PP405?
They share the same core idea: inhibiting the MPC to activate hair follicle stem cells. PP405 is the compound actually advancing through clinical trials.
Is it safe to use?
There is no safety testing behind grey-market JXL082, so that cannot be answered. It should be treated as a research compound only.
Limitations of the evidence
- It is a preclinical research compound, not an approved treatment
- No published human trial of the compound itself exists, so its safety is unverified
- In cultured human follicles, blocking the carrier suppressed rather than promoted cell growth
Notes and cautions
- Material sold online has unverified identity and purity